Fine specificity of anti-β2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1;La fine specificità degli anticorpi anti-β2 glicoproteina I nelle malattie autoimmuni sistemiche è prevalentemente diretta verso il dominio 1

Reumatismo

Volumn 63, Issue 2, 2011, Pages 91-96

  Nalli, C ^a   Andreoli, L ^a   Motta, M ^b   Norman, G L ^c   Shums, Z ^c   Binder, W L ^a   Nuzzo, M ^a   Frassi, M ^a   Lojacono, A ^b   Meini, A ^a   Medeghini, V ^a   Avcin, T ^d   Meroni, P L ^e   Tincani, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c INOVA DIAGNOSTICS INC   (United States)

^d Ospedale Pediatrico   (El Salvador)

^e ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Anti 2; Domains of 2 glycoprotein I; Glycoprotein I antibodies; Systemic autoimmune diseases

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY;

ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; CHILD; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PROTEIN DOMAIN; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; CONNECTIVE TISSUE DISEASES; DERMATITIS, ATOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; PREGNANCY; PREGNANCY COMPLICATIONS; PROTEIN STRUCTURE, TERTIARY; YOUNG ADULT;

EID: 79960582154     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Miyakis S, Lockshin MD, Atsumi T, Tincani A, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanism. Semin Thromb Haemost 2008; 34: 236-50.
3. Biggioggero M, Meroni PL. The geoepidemiology of the Antiphospholipid antibody syndrome. Autoimmun Rev 2010; 9: A299-304.
4. 2GPI. J Autoimm 2006; 27: 266-71.
5. 2glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost 2002; 87: 599-605.
6. 2-glycoprotein I antibodies in children with atopic dermatitis. Intern Immunol 2002; 14: 823-30.
7. 2-glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow up study. Am J Perinatol 2006; 23: 247-51.
8. 2-glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visit. Rheumatology 2001; 40: 565-73.
9. Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the standardisation of the antiphospholipid antibodies. Lupus 2009; 18: 913-9.
10. Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I - function in health and disease. Thromb Res 2004; 114: 335-46.
11. 2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-46.
12. De Laat B, Derksen R, Urbanus R, De Groot P. IgG antibodies that recognize epitope gly40-arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-45.
13. 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis 2011; 70: 380-3.
14. 2 glycoprotein I antibodies. A marker of antiphospholipid syndrome? Lupus 1995; 4: 122-30.
15. De Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al. The association between circulating antibodies against Domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.
16. Shoenfeld Y, Meroni PL, Cervera R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis 2008; 67: 438-42.
17. 2 glycoprotein-I-related peptides in the Antiphospholipid syndrome. J Clin Immunol 2003; 23: 377-83.
18. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental Antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999; 96: 5164-8.